EyeGene took its first step in the development of innovative biopharmaceutical drugs when it was first established in June 2000. Since

then, EyeGene has continued to research and develop innovative drugs to overcome the deterioration of the quality of life due to aging.

EyeGene has two core technologies. EGT022 is a molecule for the treatment of ischemic diseases based on proteomic research. It is being developed as a treatment for diabetic retinopathy, pressure ulcers, wound healing, and Myocardial Ischemia /Reperfusion Injury. Various premium vaccines for adults are also being developed using EyeGene 's proprietary Adjuvant, which has been established through continuous research in the field of immunology.

Ultimately, we have set a business goal to become a leader in the 21st Century Biotechnology field through the improvement in the quality of life by establishing various new treatments, preventative vaccines and diagnostic systems for the treatment and prevention of age￾related diseases.